Introduction
At the present time, we do not know whether ''the truth is out there'', but recent studies lead us to go further to take ourselves closer to finding the existence of a genetic basis for epilepsy. Mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE-HS) is the most common form of epilepsy syndromes that often remains resistant to medical therapy. 1 Although several theories have been put forth to describe the pathogenesis of HS, the main mechanism(s) comprising the cascade of events that may contribute to the etiology remain(s) obscure.
Genetic studies during the last 5 years have presented supportive [2] [3] [4] [5] as well as contradictory [6] [7] [8] [9] evidence related to the pathogenesis of MTLE-HS and the discrepancy between data previously published from different populations was mainly attributed to the ethnic differences. 10 The immune system is also another interesting field which may Seizure (2006) play a role in the pathogenesis of HS. Two major proinflammatory cytokines, interleukin-1 beta (IL1b) and interleukin-1 alpha (IL-1a) are synthesized during inflammation not only by macrophages but also by glial and neuronal cells. 11 Few studies have examined the IL-1b gene as a genetic risk factor in the development of HS but very little information related to IL-1a has been presented.
Two biallelic base chance polymorphisms in IL-1b and IL-1a genes have been reported in the long arm of the chromosome 2. In the IL-1b, one is in the promoter region at position À511 (IL-b À511) and the other is in the exon 5 at position +3953 (IL1b + 3953). 12 The IL-1a has a common polymorphism in the 5 0 regulatory region (a C to T transition at position À889 relative to the start site of transcription), which gives rise to two alleles, allele 1 and allele 2. 13 In the present study, we have analyzed the genetic polymorphism of IL-1b and -1a in patients with MTLE-HS and ethnically matched healthy blood donors. We wonder whether this cytokine gene polymorphism is responsible in part for a genetic susceptibility to MTLE-HS in the Turkish population and we wanted to contribute to the current literature with data about a different ethnic group.
Materials and methods

Patients and controls
Forty-seven patients with MTLE-HS were followed at the Cerrahpasa Medical Faculty Epilepsy Center and were included in the study. Diagnosis of MTLE-HS was made based on clinical history, electroencephalography, magnetic resonance imaging and pathologic examination of resected tissue (43 patients). The control group (n = 99) comprised unrelated, neurologically normal subjects. Both patients and controls were of Turkish ancestry. All patients or next of kin provided informed consent for the study.
Molecular methods
All individuals provided a venous blood sample and genomic DNA was prepared from blood leukocytes, as described elsewhere.
14 Each polymerase chain reaction was carried out with 50 ng genomic DNA and 1.0 U AmpliTaq Gold polymerase (Perkin-Elmer Cetus, Branchburg, NJ). For optimal amplification, the Mg + concentration of the reaction buffer was adjusted to 1.5 mM.
A single base pair polymorphism at position À511 in the promoter region and the polymorphic region containing the TaqI (New England Biolabs, Inc, Beverly, MA) restriction site at position +3953 within five of the IL-1b gene were amplified according to Mansfield and colleagues. 15 A C-T transition polymorphism at position À889 in the promoter region of the IL-1a gene was analyzed according to McDowell et al. 16 
Data analysis
The chi-square (x 2 ) or Fisher's exact test analyzed the allele frequencies between the patients and matched healthy controls, using the standard SPSS statistical program (SPSS, Chicago, Illinois, USA). A ''p'' value of less than 0.05 was considered statistically significant.
Results
The clinical characteristics of patients and controls are summarized in Table 1 . Although the age at onset of epilepsy was earlier in patients with febrile seizures (FS + ) than without (FS À ), the difference did not prove significant (90.9 AE 89.4 months vs. 114.0 AE 91.1 months, p = 0.37). No differences were also noted between FS + and FS À patients with regard to the family history of febrile seizure (FHFS) and family history of epilepsy (FHE) ( p = 0.44).
The distribution of IL-1b and IL-1a genotypes in patients with MTLE-HS and controls are demonstrated in Table 2 . The distribution of IL-1b À511 ( p = 0.66) and IL-1b + 3953 ( p = 0.42) geno-IL-1b/a polymorphisms and temporal lobe epilepsy types was not significantly different between MTLE-HS patients and controls. When compared to the MTLE-HS patients with controls with respect to IL-1a À889, the chi-square test also showed no significant result ( p = 0.14). Concerning the difference between FS + and FS À patients with respect to allele distribution, no statistically significant difference was found regarding IL-1b À511, IL-1b +3953, and IL-1a À889 ( p values 0.66, 0.47, and 0.67, respectively). One-tailed Fisher's exact test performed on the allele distribution also showed no significant difference among the groups.
In patients and controls, the homozygous (À511*1/1, +3953*1/1, and À889*1/1) and heterozygous types (À511*1/2, +3953*1/2, and À889*1/2) are commonly seen genotypes in this Turkish sample.
The level of significance was found to be 46% (delta: 0.18, alpha: 0.05 and power: 0.46) due mainly to the small number of both the patient and control groups. However, the power was taken into consideration during the statistical analysis.
Discussion
Although there are clinical and experimental studies on cytokines, antibodies and HLA system, 17, 18 immunological parameters seemed to be underestimated in the pathogenesis of HS comparing with the other etiological factors.
Following the first study by Kanemoto et al. 2 who showed the associations between polymorphism in the IL-1b gene and MTLE-HS, supportive as well as apparently contradictive studies have begun to appear in the literature. They reported an overrepresentation of the hypothesized susceptibility allele (À511T) in Japanese TLE + HS patients with a frequency of 0.63 compared with 0.46 in controls, whereas in the present study, no significant differences were observed. In a Finnish sample, Peltola et al. 3 investigated cytokine gene polymorphism in patients with drug-resistant partial epilepsy and showed that patients who carry promoter À511T allele and noncarriers of IL-IRA allele 2 are more prone to have inflammatory responses which may increase susceptibility to develop intractable epilepsy. In another study, Virta et al. 4 supported the genetic basis demonstrating an increased frequency of IL-1b À511T in children with FS and proposed that this allele may give rise to in vitro IL-1 production which may exaggerate the proinflammatory reactions during fever. Furthermore, Kanemoto et al. 5 extended their previous study by increasing the number of subjects and they examined the impact of prolonged FS on IL-1b genotype distribution. They reproduced their previous results showing that the distribution of the IL-1b À511 genotype was markedly different in patients with MTLE-HS than controls. The frequency of À511T allele was highest in patients with prolonged FS, intermediate with simple FS, and lowest without either simple or prolonged FS.
In contrast to the studies mentioned above, Heils et al. 6 in a German sample, Buono et al. 7 in an American sample, and Jin et al. 19 in Chinese samples, and the present data in a Turkish sample failed to demonstrate any significant difference in genotype and allele frequencies between MTLE-HS patients and controls. On the other hand, other studies carried out on patients with FS could not also demonstrate any association between IL-1 b and a tendency for FS (Tilgen et al. 8 in a German sample, Tsai et al. 9 in a Taiwanese sample, Kira et al. 20 in a Japanese sam-290 C. Ozkara et al. (IL-1b +3953 ) and IL-a À889 that were investigated in this study again failed to show any significant difference in the frequency distribution of alleles among controls and patients. Both genotype or allele frequencies determined here are consistent with the bulk of the studies reported in the literature that showed no association between the IL-1b nor IL-1a gene polymorphisms and temporal lobe epilepsy and FS. 4, [7] [8] [9] [19] [20] [21] However, almost all of the studies including ours, used small numbers of patients, limiting the statistical power to detect susceptibility factors of minor or moderate influence. Neverthless, this does not mean to negate or disprove the existence of a susceptibility gene which has been supported by other investigators. The differences in ethnic background may play a major role in the discrepancies obtained from the studies as well. Therefore, we need further studies with larger patient populations to discuss and consider a significant association.
Conclusion
In conclusion, no correlation was found between IL-1 a/b gene polymorphisms and MTLE-HS in Turkish patients. Apparently, this field is waiting for more research to establish a meaningful link between the immune system and epilepsy.
